Insider Selling: Twist Bioscience (NASDAQ:TWST) Insider Sells 1,019 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 1,019 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $32.08, for a total transaction of $32,689.52. Following the sale, the insider owned 120,694 shares of the company’s stock, valued at approximately $3,871,863.52. This represents a 0.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Dennis Cho also recently made the following trade(s):

• On Thursday, October 30th, Dennis Cho sold 6,515 shares of Twist Bioscience stock. The shares were sold at an average price of $31.44, for a total value of $204,831.60.
• On Monday, October 6th, Dennis Cho sold 3,876 shares of Twist Bioscience stock. The stock was sold at an average price of $32.19, for a total transaction of $124,768.44.
• On Monday, September 22nd, Dennis Cho sold 233 shares of Twist Bioscience stock. The stock was sold at an average price of $27.56, for a total transaction of $6,421.48.
• On Monday, September 15th, Dennis Cho sold 94 shares of Twist Bioscience stock. The shares were sold at an average price of $25.33, for a total transaction of $2,381.02.
• On Monday, September 8th, Dennis Cho sold 269 shares of Twist Bioscience stock. The stock was sold at an average price of $25.76, for a total transaction of $6,929.44.

Twist Bioscience Stock Performance

Shares of TWST stock traded up $1.46 during mid-day trading on Wednesday, reaching $31.52. 1,393,309 shares of the company’s stock traded hands, compared to its average volume of 1,310,130. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. The firm has a market capitalization of $1.90 billion, a PE ratio of -21.74 and a beta of 2.43. Twist Bioscience Corporation has a 12 month low of $24.07 and a 12 month high of $55.33. The firm has a 50 day moving average price of $29.10 and a two-hundred day moving average price of $31.74.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. The company had revenue of $96.06 million during the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. On average, research analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on TWST shares. Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Evercore ISI lowered their price target on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Stephens began coverage on shares of Twist Bioscience in a research note on Monday. They set an “overweight” rating and a $41.00 price objective for the company. Barclays lowered their target price on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a report on Thursday, October 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a report on Wednesday, October 8th. Ten research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $47.80.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently modified their holdings of TWST. GAMMA Investing LLC increased its holdings in shares of Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after acquiring an additional 303 shares in the last quarter. D.A. Davidson & CO. increased its stake in Twist Bioscience by 8.0% during the 1st quarter. D.A. Davidson & CO. now owns 22,710 shares of the company’s stock valued at $892,000 after purchasing an additional 1,682 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Twist Bioscience by 27.3% in the first quarter. Envestnet Asset Management Inc. now owns 70,279 shares of the company’s stock worth $2,759,000 after buying an additional 15,085 shares during the last quarter. Xponance Inc. raised its holdings in shares of Twist Bioscience by 22.0% in the first quarter. Xponance Inc. now owns 5,953 shares of the company’s stock worth $234,000 after buying an additional 1,072 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in shares of Twist Bioscience by 2.4% during the first quarter. New York State Common Retirement Fund now owns 452,750 shares of the company’s stock worth $17,775,000 after buying an additional 10,761 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.